This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.

Start Date01 Dec 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT07901270

/ Not yet recruitingNot Applicable

Metabolic Remodelling in Worsening Heart Failure Treated With Vericiguat: A Prospective Multi-Omics Study Integrating Cardiac Imaging and Endothelial Function

Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention. Vericiguat is a medication used in certain patients with heart failure whose symptoms have recently worsened.
The aim of this study is to better understand how vericiguat treatment is associated with changes in metabolism, heart function, and blood vessel health in patients with heart failure.
This is a prospective, observational study conducted at a single hospital in Italy. Researchers will collect clinical information and analyze biological samples to investigate changes in molecules involved in energy production, inflammation, and cardiovascular function. Heart imaging and assessments of blood vessel function will also be used to better understand the patients' cardiovascular health.
The study will explore whether these biological and cardiovascular measurements are associated with treatment with vericiguat and whether they could help identify patients who may benefit most from this therapy.
The results may improve our understanding of heart failure and support more personalized treatment strategies in the future.

Start Date01 Nov 2026

Sponsor / Collaborator

University of Salerno

ChiCTR2600134550

/ SuspendedNot ApplicableIIT

A single-dose, randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of Vericiguat Tablets in healthy trial participants under fed conditions

Start Date01 Oct 2026

Sponsor / Collaborator-

100 Clinical Results associated with Vericiguat

100 Translational Medicine associated with Vericiguat

100 Patents (Medical) associated with Vericiguat

440

Literatures (Medical) associated with Vericiguat

01 Jan 2027·CURRENT PROBLEMS IN CARDIOLOGY

Targeting the NO–sGC–cGMP pathway in cancer therapy-related cardiac dysfunction: the emerging role of vericiguat

Review

Author: Gallina, Sabina ; Saraullo, Silvio ; Genovesi, Eugenio ; Marino, Mario Di ; Marco, Massimo Di ; Renda, Giulia ; Rossi, Davide ; Magnano, Roberta ; Pezzi, Laura ; Scollo, Claudio ; Pierfelice, Francesca ; D'Alleva, Alberto

Cancer therapy-related cardiac dysfunction (CTRCD) remains a major limitation of modern oncology, potentially compromising cardiovascular prognosis, functional status, and continuation of effective anticancer therapy. Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, enhances nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) signalling and has emerged as a biologically plausible candidate for translational evaluation in CTRCD. Chronic doxorubicin exposure reduces cardiac sGC activity, and genetic or pharmacological modulation of this pathway modifies experimental anthracycline injury. A 2024 peer-reviewed study in human AC-16 cardiomyocyte cells and primary skeletal-muscle cells showed increased cGMP and attenuation of NLRP3/MyD88-associated inflammatory and cytotoxic signalling with vericiguat. Two independent full-length studies published in 2026 extended this signal, implicating inhibition of ferroptosis through restoration of SLC7A11/GPX4-related defence and suppression of glycolysis, histone lactylation, and RELB-dependent inflammatory signalling. These findings strengthen mechanistic plausibility but remain preclinical. In heart failure, SOCRATES-REDUCED supported dose selection, VICTORIA demonstrated a modest reduction in cardiovascular death or first heart-failure hospitalization after recent worsening HFrEF, whereas VICTOR had a neutral primary endpoint in more stable ambulatory HFrEF; pooled analyses nevertheless suggest an overall treatment signal across the HFrEF risk spectrum. No randomized outcome trial has demonstrated efficacy specifically in CTRCD. ELEVATE (NCT05806138), a small randomized phase II trial in breast-cancer-associated CTRCD, remains without reported efficacy results as of 9 September 2026. Vericiguat should therefore be considered a biologically coherent and clinically testable strategy rather than an established cardio-oncology therapy.

01 Jan 2027·MICROVASCULAR RESEARCH

Vericiguat prevents hepatic inflammation and microcirculatory dysfunction in the early phase of sepsis in mice

Article

Author: Ampofo, Emmanuel ; Wilden, Cedric ; Steiner, Luzius A ; Laschke, Matthias W ; Grob, Christian A

Sepsis remains a major cause of morbidity and mortality worldwide, with persistent microcirculatory dysfunction driving progressive organ injury despite optimal macrocirculatory support. Vericiguat, a soluble guanylate cyclase (sGC) stimulator approved for chronic heart failure, enhances nitric oxide signaling, promoting vasodilation and supporting endothelial integrity. Based on this profile of action, we hypothesized that vericiguat improves hepatic microcirculatory perfusion in sepsis and thereby mitigates liver injury. Male C57BL/6J mice underwent sham surgery (n = 8) or cecal ligation and puncture (CLP). CLP-treated mice received either vericiguat (3 mg/kg body weight; n = 8) or dimethyl sulfoxide (DMSO) 50% as vehicle control (n = 8). Six hours later, the livers were examined by means of intravital fluorescence microscopy, followed by immunohistochemical and plasma analyses. Vericiguat significantly reduced leukocyte-endothelial cell interactions and macromolecular leakage in the microcirculation of septic livers. Moreover, it reduced sinusoidal perfusion failure and normalized the expression of the extracellular matrix marker perlecan. Plasma analyses did not reveal marked differences between vericiguat- and vehicle-treated septic mice, most probably due to the early observation time point after CLP. Taken together, these findings suggest that vericiguat may represent a promising drug in sepsis, potentially preventing early hepatic inflammation and microcirculatory dysfunction.

01 Dec 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Soluble guanylate cyclase stimulators and activators: Chemistry, biology, and therapeutic advances

Review

Author: Chen, Mao ; Yang, Haoran ; Zuo, Zeping ; Feng, Qipu ; Ran, Junpeng

The discovery of soluble guanylate cyclase (sGC) stimulators and activators has provided invaluable tools for elucidating nitric oxide (NO)-sGC signaling and has opened up novel therapeutic opportunities for cardiovascular diseases and beyond. In recent years, sGC modulators have garnered widespread attention as promising agents for diseases such as pulmonary hypertension, heart failure, chronic kidney disease, and diabetic retinopathy-with sGC stimulators and sGC activators emerging as key research focuses in this field. Although first-in-class sGC stimulators (e.g., riociguat, vericiguat) and activators (e.g., cinaciguat) have advanced into clinical use or development, most subsequent candidates continue to be refined to optimize efficacy, safety, and target selectivity. This review provides a comprehensive and systematic exploration of sGC stimulators and sGC activators in the context of disease therapy. Specifically, these small molecules are classified and elaborated based on their mechanisms of action, structural characteristics, and development trajectories; for each category, the binding modes, structural features, and pharmacological activities of representative compounds are analyzed in detail, while their inherent advantages and limitations are critically evaluated. Collectively, this review offers valuable insights and guidance for the future research and development of safer, more effective, and more precisely targeted sGC modulators.

News (Medical) associated with Vericiguat

03 Nov 2026

·www.biospace.com

HLS Therapeutics Partners with Bayer to Commercialize VERQUVO® in Canada

VERQUVO® is authorized and available in Canada, with public and private reimbursement in place. VERQUVO® is an oral treatment indicated for symptomatic chronic heart failure. HLS will assume responsibility for distribution, promotion and medical education support for VERQUVO®. The agreement marks HLS's entry into heart failure and strengthens the Company's position in the Canadian cardiovascular market. TORONTO , Nov. 3, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into an agreement with Bayer Inc. ("Bayer") to commercialize VERQUVO® (vericiguat) in Canada. VERQUVO® has been authorized in Canada since April 2023 and is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or IV diuretic therapy. VERQUVO® should be used in combination with standard-of-care therapy for heart failure. The approval was supported by the pivotal Phase 3 VICTORIA trial 1 . VERQUVO® is an oral, once-daily medication that is available in Canada today, with public and private reimbursement in place. Under the agreement, HLS will assume responsibility for commercial and medical education activities for VERQUVO® in Canada, including promotion to healthcare professionals, distribution to wholesalers and the recording of net sales. HLS will assume these responsibilities and begin recording net sales effective from the first quarter of 2027. Bayer will continue to hold the market authorization for VERQUVO® in Canada, will retain responsibility for regulatory, pharmacovigilance, pricing and reimbursement matters, and will supply product to HLS. Heart failure is a serious and growing health problem in Canada and a leading cause of hospitalization. An estimated 750,000 Canadians are living with heart failure and approximately 100,000 people are diagnosed with the condition each year. 2 "For Canadians living with heart failure, a worsening event that leads to hospitalization or an emergency department visit can mark a critical turning point, as it carries a high risk of further hospitalizations. VERQUVO® (vericiguat) is an additional treatment option, used alongside standard care for adults with symptomatic chronic heart failure and reduced ejection fraction who have stabilized after a recent hospitalization or intravenous diuretic treatment," said Dr. Justin Ezekowitz, Cardiologist, University of Alberta in Edmonton and Principal Investigator of the VICTORIA Trial. "VERQUVO® gives us an entry into heart failure and is aligned with our stated BD strategy of adding medicines that fit our organizational capabilities," said Craig Millian, CEO at HLS. "This addition builds on our cardiovascular portfolio, moves us into a new area of care, and reinforces our leadership in cardiovascular medicine in Canada." "We look forward to working together with HLS to support the continued commercialization of VERQUVO® in Canada," said Viktoria Friedrich, President and CEO, Bayer Canada. HLS will pay Bayer royalties on net sales of VERQUVO® in Canada, along with potential one-time payments tied to the achievement of commercial milestones. HLS will fund these through existing resources. ABOUT VERQUVO® (vericiguat) VERQUVO® (vericiguat) is a prescription medicine authorized for sale in Canada and reimbursed across multiple public and private drug plans. Bayer will continue to hold the Canadian market authorization. ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: ABOUT BAYER Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, Bayer aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, Bayer employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, visit: REFERENCES 1: Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893. 2: Heart and Stroke Foundation of Canada; hs-heart-failure-report-2022-final.pdf FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 11, 2026, and Management's Discussion and Analysis dated August 11, 2026, both of which have been filed on SEDAR+ and can be accessed at . Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE HLS Therapeutics Inc.

Drug ApprovalPhase 3License out/in

14 May 2026

·firstwordpharma.com

Biopharma bites: Rigel buys beleaguered PROTAC, Bayer's pipeline trim, and more from Novo Nordisk, Delos Capital

Rigel gets hands on Pfizer's recently-approved breast cancer drug Bayer cuts early-stage assets from pipeline Superior weight loss in Wegovy HD early responders 'First-of-its-kind' collab aims to incubate new biotechs Rigel gets hands on Pfizer's recently-approved breast cancer drug Having signalled their intent last year to find a US commercialisation partner for vepdegestrant, Pfizer and Arvinas reached an agreement with Rigel Pharmaceuticals on Tuesday to both market and further develop the PROTAC oestrogen receptor (ER) degrader. The deal comes a matter of weeks after the FDA approved the oral drug as Veppanu for ER-positive, HER2-negative, advanced or metastatic breast cancer in adults carrying ESR1 mutations and who have progressed after at least one line of endocrine therapy (see – Spotlight On: Uncertain future resolved for Pfizer and Arvinas' once heavily touted breast cancer drug as Rigel steps in). Under the agreement, Pfizer and Arvinas will receive $85 million in upfront and transition payments, with the potential for a further $320 million in development, regulatory and commercial milestones, plus tiered sales royalties in the mid-teens to mid-20s. All payments from Rigel will be split evenly between the two companies. Pfizer itself had paid Arvinas $650 million upfront in 2021 to co-develop and co-commercialise vepdegestrant, but subsequent clinical readouts narrowed the addressable patient population. For its part, Rigel will own global rights to vepdegestrant, allowing it to sublicense the therapy to potential partners for development and marketing outside of the US. -Matt Dennis Bayer cuts early-stage assets from pipeline As part of its first-quarter earnings report Tuesday, Bayer disclosed that it has cut two Phase I programmes from its pipeline and halted development of Verquvo (vericiguat) in adults with stable chronic heart failure (CHF) and reduced ejection fraction (HFrEF). In September, the pharma, alongside partner Merck & Co., reported that the sGC stimulator — approved in the US and EU for certain patients with worsening CHF — failed to meet its primary endpoint in a Phase III trial for HFrEF. The axed early-stage assets include BAY 2701250, an atrial natriuretic peptide (ANP)-based candidate that was in Phase I testing for pulmonary hypertension. According to ClinicalTrials.gov, the 82-person study finished last May. The third cut programme is BAY 3178275, a Phase I-stage GPR84 antagonist being developed for diabetic neuropathic pain.-Elizabeth Eaton Superior weight loss in Wegovy HD early responders New sub-analyses from the pivotal STEP UP trial show Novo Nordisk's 7.2-mg semaglutide injectable formulation (marketed as Wegovy HD) resulted in a ~28% weight loss among 'early responders' — outclassing the 20.7% reduction originally seen in the wider study. Data presented Tuesday at the European Congress on Obesity (ECO) revealed that early responders — defined as those achieving ≥15% body weight loss within 24 weeks — accounted for 27% of Wegovy HD recipients, compared with 21% for the 2.4-mg dose and 3% on placebo. Novo said that the early responders on Wegovy HD lost on average 27.7% of their weight by week 72, versus. Moreover, a separate MRI sub-analysis with STEP-UP confirmed that 84% of weight lost was attributable to fat mass reduction, including a >30% decrease in abdominal visceral fat, with muscle function largely preserved. For further analysis, see — Spotlight On: Early responder analysis could be useful catalyst for Wegovy HD in US obesity showdown. -Pavan Kamat 'First-of-its-kind' collab aims to incubate new biotechs In what is being touted as a "first-of-its-kind" collaboration, life sciences investment firm Delos Capital is partnering with biopharmaceutical company AP Biosciences to create and incubate new biotechs. The tie-up combines Delos' company-building expertise with APBio's antibody discovery platforms in an effort to accelerate novel medicines through clinical proof of concept. The collaboration will also take advantage of APBio's operational efficiency in Greater China, which the parties noted enables "faster and more capital-efficient translation from innovative concepts to clinical-stage assets." The companies will initially focus on autoimmune diseases using bi- and tri-specific antibody approaches that combine novel and de-risked targets and mechanisms, with Delos — through its Delos Foundry — leading therapeutic ideation, financing and strategic development. "This collaboration allows us to extend the impact of our antibody discovery platforms beyond our internal pipeline," said Jeng Her, APBio's chief executive. Meanwhile, Henry Chen, founder and managing partner of Delos noted that "if we don't see existing companies that match one of our investment theses, our team can fill that gap by incubating innovative assets in a US-based NewCo." -Matt Dennis The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

06 May 2026

·www.biospace.com

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6 th May 2026 Immutrin Ltd, (“Immutrin” or “the Company”) a biotechnology company developing next generation antibody therapy to reverse amyloidosis, today announces the appointment of Dr Robert Blaustein, MD, PhD as Chief Medical Officer (CMO). The Company also announces the establishment of its US subsidiary. Robert brings extensive experience in cardiovascular clinical research and drug development, with a proven track record of advancing innovative therapeutics from early development through regulatory filing and approval. He will build out Immutrin’s clinical team and lead the Company’s clinical development and regulatory strategy as it advances towards first-in-human studies. “ Appointing our Chief Medical Officer marks a pivotal milestone for Immutrin as we evolve into a clinical-stage organization ,” said Mihriban Tuna, Chief Executive Officer at Immutrin . “ Robert’s deep expertise in cardiovascular medicine and proven leadership in clinical development will be instrumental as we advance our lead asset towards first-in-human studies .” Prior to joining Immutrin, Robert served as Chief Development Officer at Edgewise Therapeutics, where he led development of the novel cardiac sarcomere modulator EDG-7500 and oversaw the company’s broader cardiovascular clinical stage pipeline. Earlier in his career, he spent more than 15 years at Merck, where he led late-stage development programs in atherosclerosis and heart failure. Notably, he led the vericiguat development team through the successful completion of the Phase 3 VICTORIA heart failure trial, as well as the subsequent regulatory filing and global approval of vericiguat for patients with worsening heart failure, in collaboration with Bayer. Robert earned his undergraduate degree in mathematics from Wesleyan University. He completed his MD/PhD training at Albert Einstein College of Medicine, medical residency at Brigham and Women’s Hospital, and cardiology fellowship at Massachusetts General Hospital. Following, an HHMI postdoctoral fellowship in the Department of Biochemistry at Brandeis University, he then served on the faculty at Tufts Medical Center before transitioning to industry with Merck. “ I am excited to join Immutrin at such an important stage of its journey ,” said Dr. Blaustein, Chief Medical Office at Immutrin. “While current therapies for amyloidosis can slow disease progression, they do not remove existing amyloid deposits. The Company’s novel antibody approach, designed to selectively target and clear deposited amyloid, offers a promising strategy to address the underlying pathology. I look forward to advancing this innovative therapy into clinical development .” In parallel with this leadership appointment, Immutrin has established a US subsidiary, Immutrin US Inc., to support planned clinical activities in North America. ENDS About Immutrin Immutrin is a biotechnology company developing the next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils. Immutrin was co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys, FRS; Nobel Laureate Sir Gregory Winter, FRS; and Professor Daniel Christ and is built on decades of scientific and clinical leadership in amyloidosis combined with groundbreaking antibody expertise in drug development. Immutrin is led by an experienced management team and supported by other leading global investors including Frazier Life Sciences, F-Prime, Qiming Venture Partners and SR One. For more information visit . For media inquiries, please contact: ICR Healthcare Mary-Jane Elliott / Sarah Elton-Farr/ Stephanie Cuthbert immutrin@icrinc.com Tel: +44 (0) 20 3709 5700

Executive Change

100 Deals associated with Vericiguat

External Link

KEGG	Wiki	ATC	Drug Bank
D11051	Vericiguat	C01DX22 C01DX	DB15456

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Reduced ejection fraction co-occurrent and due to chronic heart failure	China	Bayer AG	18 May 2022
Chronic heart failure	European Union	Bayer AG	16 Jul 2021
Chronic heart failure	Iceland	Bayer AG	16 Jul 2021
Chronic heart failure	Liechtenstein	Bayer AG	16 Jul 2021
Chronic heart failure	Norway	Bayer AG	16 Jul 2021
Heart Failure	United States	Merck Sharp & Dohme LLC	19 Jan 2021
Shock	United States	Merck Sharp & Dohme LLC	19 Jan 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Left ventricular systolic dysfunction	Phase 3	Brazil	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Canada	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Denmark	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	France	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Germany	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Italy	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Netherlands	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	South Korea	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Spain	Merck Sharp & Dohme LLC	31 May 2023
Left ventricular systolic dysfunction	Phase 3	Sweden	Merck Sharp & Dohme LLC	31 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2026	Not Applicable	-	41	Vericiguat	mqtecgjsho(cknxaxwgrj) = uvxibbfbma xucbzcerry (nyklvrwcbv ) View more	Positive	31 Aug 2026
ESC2026	Not Applicable	Heart failure with reduced ejection fraction	732	Vericiguat (VICTORIA-like)	uzuvueswxj(ggtyhhctqn) = rjlnpjkxxg pbcznfwxnk (xxzxwaslcc ) View more	Positive	29 Aug 2026
				Vericiguat (VICTOR-like)	uzuvueswxj(ggtyhhctqn) = lvuqbodcia pbcznfwxnk (xxzxwaslcc ) View more
VICTOR (ESC2026)	Phase 3	Heart Failure	6,105	Vericiguat	viphndxrkk(kvyghvgitb) = rfnhzxoylm uvhlwtqvzd (zhqcdzqshk ) View more	Positive	28 Aug 2026
				Placebo	viphndxrkk(kvyghvgitb) = hmnddbbwls uvhlwtqvzd (zhqcdzqshk ) View more
OpTIMa-HF (ESC2026)	Not Applicable	Heart failure with reduced ejection fraction	685	Vericiguat	yrczgesgqv(yqgnbsvxdu) = hcvaaepubi qzwcefwnys (axfhcmscej ) View more	Positive	28 Aug 2026
NCT06415227 (ViVA, Pubmed \| J Am Coll Cardiol)	Phase 2	Coronary Vasospasm	57	Vericiguat	kerhjohtrk(vqfccxvekz): OR = 0.84 (95.0% CI, 0.65 - 1.04) View more	Negative	01 Aug 2026
				Placebo
ESC2026	Not Applicable	Heart failure with reduced ejection fraction	212	Vericiguat	etfxcfzpvl(pwiyxtswvd) = oxnkzdtdnh wmmckdhbfi (fczzlmerfm ) View more	Positive	11 May 2026
OPTIMA-HF (ESC2026)	Not Applicable	Heart Failure	572	Vericiguat (<75 years)	ftjnxnoqjm(qukbmkbyes) = qzkhpsqdrt cfwhxeqxnh (yofkmrwqrc ) View more	Positive	10 May 2026
				Vericiguat (≥75 years)	ftjnxnoqjm(qukbmkbyes) = itwjbjsjsa cfwhxeqxnh (yofkmrwqrc ) View more
VERISEC (ESC2026)	Not Applicable	Heart Failure	835	Vericiguat	zmoydbxhjq(tzcerbgfyy) = coyixgvhys vnupfeslux (nhwcykfaey, 1.07) View more	Positive	10 May 2026
NCT05420012 (Pubmed \| Am J Cardiol)	Phase 2	Heart failure with reduced ejection fraction	26	Vericiguat	xejvpmfgbj(omgajnqujw): Difference (%) = 0.7 (95.0% CI, -1.1 to 2.5), P-Value = 0.4 View more	Positive	01 Feb 2026
				Placebo
NCT05711719 (CTgov)	Phase 2	Metabolic Syndrome \| Coronary microvascular dysfunction \| Anomalous Left Coronary Artery	45	Vericiguat (Vericiguat)	exxkvyrilt(oyubfxnbuy) = fwkolnxtal ulzfpvzhhz (xpdwmkvedc, 1.28) View more	-	27 Jan 2026
				Placebo (Placebo)	exxkvyrilt(oyubfxnbuy) = zllsnwvqxj ulzfpvzhhz (xpdwmkvedc, 1.18) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis